Advertisement

Advertisement

JP:520A Stock Latest News

J-Pharma Wins AMED Backing for Global Biliary Tract Cancer Trial

Company AnnouncementsJ-Pharma Wins AMED Backing for Global Biliary Tract Cancer Trial

J-Pharma Signs Global Licensing Term Sheet for Neuro-Inflammation Drug JPH034

PremiumCompany Announcements

J-Pharma Signs Global Licensing Term Sheet for Neuro-Inflammation Drug JPH034

12d ago

J-Pharma Finalizes Restricted Stock Issuance and Tweaks Option Exercise Prices

PremiumCompany Announcements

J-Pharma Finalizes Restricted Stock Issuance and Tweaks Option Exercise Prices

2M ago

J-Pharma Posts Quarterly Loss and Confirms Full-Year Red-Ink Forecast After TSE Growth Listing

PremiumCompany Announcements

J-Pharma Posts Quarterly Loss and Confirms Full-Year Red-Ink Forecast After TSE Growth Listing

2M ago

J-Pharma Launches Restricted Stock Compensation for Directors and Executives

PremiumCompany Announcements

J-Pharma Launches Restricted Stock Compensation for Directors and Executives

3M ago

J-Pharma Advances Global Oncology Pipeline With Lead Drug Nanvuranlat

PremiumCompany AnnouncementsJ-Pharma Advances Global Oncology Pipeline With Lead Drug Nanvuranlat

3M ago

J-Pharma to Restructure Capital Surplus to Eliminate Retained Earnings Deficit

Company Announcements

J-Pharma to Restructure Capital Surplus to Eliminate Retained Earnings Deficit

5M ago

J-Pharma to Introduce Restricted Stock Plan to Align Directors With Shareholders

Company Announcements

J-Pharma to Introduce Restricted Stock Plan to Align Directors With Shareholders

5M ago

J-Pharma Overhauls Board and Creates CBO Role to Drive Global Growth

PremiumCompany Announcements

J-Pharma Overhauls Board and Creates CBO Role to Drive Global Growth

5M ago

J-Pharma Flags Risks and Uncertainty in FY2026 Earnings Presentation

PremiumCompany Announcements

J-Pharma Flags Risks and Uncertainty in FY2026 Earnings Presentation

5M ago

J‑Pharma Advances Nanvuranlat Into Pivotal Biliary Tract Cancer Trial: What Investors Should Watch

PremiumCompany Announcements

J‑Pharma Advances Nanvuranlat Into Pivotal Biliary Tract Cancer Trial: What Investors Should Watch

5M ago

J-Pharma Books Over JPY 1 Billion in AMED Grant Income for MS Drug R&D

PremiumCompany Announcements

J-Pharma Books Over JPY 1 Billion in AMED Grant Income for MS Drug R&D

5M ago

J-Pharma Widens Annual Loss but Bolsters Equity and Cash to Fund R&D

PremiumCompany AnnouncementsJ-Pharma Widens Annual Loss but Bolsters Equity and Cash to Fund R&D

5M ago

J‑Pharma’s JPH034 Phase 1 Trial: Early Safety Data in Focus for Investors

Company Announcements

J‑Pharma’s JPH034 Phase 1 Trial: Early Safety Data in Focus for Investors

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >